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ABSTRACT
Abnormal activation of hedgehog pathway signaling is a key
driver in the pathogenesis of basal cell carcinoma (BCC).
Vismodegib, a first-in-class small-molecule inhibitor of hedge-
hog pathway signaling, is approved by regulatory authorities
for the treatment of adults who havemetastatic BCC or locally
advanced BCC that has recurred after surgery, or who are not
candidates for surgery and who are not candidates for
radiation. A second inhibitor, sonidegib, was also recently
approved for the same patient group with locally advanced
BCC. Adverse events (AEs) commonly observed in hedgehog
pathway inhibitor (HPI)-treated patients include muscle
spasms, ageusia/dysgeusia, alopecia, weight loss, and asthenia
(fatigue).These AEs are thought to bemechanistically related
to inhibition of the hedgehog pathway in normal tissue.
Although the severity of the majority of AEs associated with
HPIs is grade 1–2, the long-term nature of these AEs can lead
to decreased quality of life, treatment interruption, and
in some cases discontinuation, all of which might affect
clinical outcome.The incidence, clinical presentation, putative
mechanisms, and management strategies for AEs related
to HPIs in advanced BCC are described. These observa-
tions represent the first step toward the development of
mechanism-based preventive and management strate-
gies. Knowledge of these AEs will allow health care pro-
fessionals to provide appropriate counseling and supportive
care interventions, all of which will contribute to im-
proved quality of life and optimal benefit from therapy.
The Oncologist 2016;21:1–12
Implications for Practice: The hedgehog pathway inhibitors (HPIs) vismodegib and sonidegib represent a therapeutic
breakthrough forpatientswith advancedbasal cell carcinoma.However, thenatureof the low-gradeadverseevents (AEs) commonly
observed in HPI-treated patients, includingmuscle spasms, ageusia/dysgeusia, alopecia, weight loss, and fatigue, can impact clinical
outcomes as a result of decreased quality of life and treatment discontinuation. The incidence, clinical presentation, putative
mechanisms, and management strategies for AEs related to administration of HPIs are described, with the goal of enabling health
care professionals to provide appropriate counseling and supportive care interventions to their patients.
INTRODUCTION
Abnormal activation of hedgehog pathway signaling, ob-
served in.90%ofcasesofbasal cell carcinoma (BCC) [1, 2], is a
keydriver in thepathogenesis of BCC. Although themajority of
BCCs can be successfully treated with surgery, topical
agents, or radiation, hedgehog pathway inhibition has been
a therapeutic breakthrough for patients with advanced
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disease (locally advanced BCC [laBCC] or metastatic BCC
[mBCC]; it is estimated that metastatic disease develops in
,1% of patients) [1, 2]. Vismodegib was the first hedgehog
pathway inhibitor (HPI) to be approved for the treatment of
adults who have mBCC or laBCC that has recurred after
surgery or who are not candidates for surgery and are not
candidates for radiation treatment (approval granted by the
U.S. Food andDrug Administration [FDA] in January 2012 [3]
and the EuropeanMedicines Agency [EM]) in July 2013 [4]).
In 2015, a second HPI (sonidegib) was approved by both the
FDA and the EMA for patients with laBCC, based on data
from the Basal Cell Carcinoma Outcomes with LDE225
Treatment (BOLT) study [5].
The safety profile of vismodegib is consistent within
clinical trials and general clinical practice [6–12]. Commonly
observed adverse events (AEs) include muscle spasms,
ageusia/dysgeusia, alopecia, weight loss, and asthenia
(fatigue). Similarly, the most commonly observed AEs in
sonidegib-treated patients in the BOLTstudy includedmuscle
spasms, alopecia, dysgeusia, nausea, increased blood creatine
kinase level, asthenia, and weight loss [5]. Many of these AEs
are thought to be mechanistically related to inhibition of the
hedgehog pathway. Although the majority of AEs associated
with HPIs are grade 1–2, they tend to be long-term and
interferewithpatientqualityof life (QOL), leadingtotreatment
interruption and discontinuation that may preclude the
intended therapeutic effect.Therefore, appropriate strategies
for the prevention and management of AEs are essential to
ensure that patients can continue to receive and benefit from
HPI treatment.
The Hedgehog Signaling Pathway
The hedgehog signaling pathway is critical for normal
embryonic development and patterning [2]. In normal cells,
the canonical hedgehog signaling pathway is activated by the
binding of hedgehog ligands to their receptor protein patched
homolog 1 (Patched; PTCH1). Ligand binding relieves the
inhibitoryeffects of PTCH1on the Smoothenedprotein (SMO).
Signal transduction by SMO leads to activation and nuclear
translocation of Gli transcription factors and induction of
target genes, many of which are involved in proliferation,
survival, and differentiation. In addition to the canonical
signaling pathway, several noncanonical hedgehog signal-
ing pathways have been identified [13, 14]. Inappropriate
reactivation of the hedgehog signaling pathway can result
in tumorigenesis, and it was first described in basal cell
carcinoma nevus syndrome (BCCNS), also known as Gorlin
syndrome [15–17]. In BCC, the hedgehog signaling pathway
is typically activated by mutations that lead to dysfunction
of the PTCH1 gene, seen almost universally in patients with
BCCNS and in most patients with sporadic BCC tumors. An
estimated 80%–90% of sporadic BCC tumors have PTCH1
mutations, whereas 10%harbor SMOmutations. Both types
of mutations lead to constitutive SMO signaling and BCC
development [2].
Although hedgehog signaling is silenced in most normal
adult tissues, it has been shown to play a role in the repair of
damaged tissues, the promotion of stemcell proliferation, and
the regulation of maintenance of various tissues, including
muscle, hair, taste buds, and the reproductive system [1, 18].
After injury, sonic hedgehog (Shh) signaling is reactivated in
adult skeletalmuscle and plays a functionally important role in
regeneration by regulating injury-induced angiogenesis and
myogenesis [19]. Pathway inhibition impairs production of
angiogenic factors, decreases muscle blood flow, and reduces
capillarydensity after injury [19]. Hedgehog signaling has been
shown to regulate development and maintenance of taste
buds and seems to play a critical role in taste function integrity
[20, 21].Adultmice treatedwithvismodegibdisplay significant
reductions in taste-bud size and number of taste cells, and
decreased behavioral responses to sweet and bitter stimuli
[21]. Interestingly, hedgehog-responding cells were lost in
fungiform papilla epithelium in sonidegib-treated mice, with
taste-bud remnants entirely absent or severely decreased in
.90% of aberrant papillae [22]. The hedgehog signaling
pathway is alsoactive in thehair follicle, transitioninghair from
thetelogen (resting) to theanagen (activegrowth)phaseof the
growth cycle [23–25]. Shh-nullmice (inwhich the Shh genehas
been knocked out) exhibit follicles arrested at the hair germ
stage of development [23, 24]. In mice, transient over-
expression of Shh by gene transfer or topical application of a
hedgehog agonist induces resting hair follicles to enter
anagen, resulting in hair growth [25, 26]. Antibodies that
block the activity of Shh are able to prevent hair growth in
adult mice [27].
HPI Safety Profile
HPI safety data are available from a number of key studies
(Table 1) [5–12]. Nearly all patients treated with HPIs
experience at least one treatment-emergent AE (TEAE), with
an incidence rate of 95%–100%observed across studies. In the
RegiSONIC disease registry, protocol specified-related AEs
were reported in 82% of the first 109 patients with laBCC
givenvismodegib [6–11].Themost frequentAEsobservedwith
HPIs include muscle spasms, alopecia, dysgeusia, weight loss,
asthenia, nausea, decreased appetite, and diarrhea (Table 2)
[5–12]. The majority of AEs are mild or moderate (grade 1–2)
and occur early in the course of treatment [6–11]. Reported
rates of discontinuation because of all AEs vary across studies
(e.g., 5% in the12-weekoperableBCCstudy [11]and36%in the
Study of Vismodegib in Patients With Locally Advanced or
Metastatic Basal Cell Carcinoma (STEVIE) [median duration
of treatment 36.4 weeks] [12]). In addition, data from the
ERIVANCEBCC30-monthanalysis [8] and theSTEVIE study [12]
show that the severity of AEs did not worsen with longer
treatment duration. Reasons for discontinuation vary depend-
ing on the type of advanced BCC; patientswith laBCC aremore
likely to request discontinuation because of AEs, whereas
patients with mBCC often discontinue because of disease
progression [6]. However, it has been observed that patients
who discontinued because of a grade 1 or 2 AE often
experience complete or partial response before discontinua-
tion [12]. Itmaybe that somepatients discontinue vismodegib
when a response has been achieved and if the grade 1–2 AEs
(considered “annoying”) are significantly impacting QOL. A
similar safety profile was reported with sonidegib in the BOLT
study [5] and in the subsequent 18-month follow-up [28].
There is a clear need to educate health care professionals
(HCPs) and patients regarding AEmanagement strategies that
allow patients to continue treatment.
©AlphaMed Press 2016
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Prevention and Management Strategies for
HPI-Related Adverse Events
Because themajorityofAEsemergeearly in treatment, patient
education is key in terms of what to expect and the possible
management options. It is recommended that physicians
follow their local prescribing information.Treatment interrup-
tion is a commonapproach, andHCPs andpatients should be
encouraged to continue supportive care interventions after
re-exposure. A thorough baseline examination is also impor-
tant, including an evaluation of comorbidities (i.e., alopecia,
myopathies, diabetes, gastrointestinal/liver disease, and
sensory and motor neuropathies) and concomitant medi-
cations that might contribute to tolerability issues (e.g.,
glucose-lowering or diarrhea-causing agents, or neurotoxic,
hepatotoxic,ormyotoxicmedications). Finally, theAEsand their
associated management strategies (Figs. 1, 2; Table 3) [29]
should be considered in the context of the benefit of HPI
treatment and the rapid clinical response. Because most of the
AEs induced byHPIs have a significant subjective component, it
would be important to include questions specific to these
untoward events during clinical evaluations. Although a
patient-reported outcomes questionnaire was recently
developed for use in patients with BCC (Advanced Basal
Cell Carcinoma Index) [30], it is not specific for AEs related
to HPIs. Preliminary studies have yielded a questionnaire
that, although it has not been validated, addresses some of
themost common HPI toxicities and their impact on patient
QOL (Fig. 3). This questionnaire would be useful in routine
clinical care of patients treated with HPIs and in supportive
care trials.
Muscle Spasms
In general, intensity of HPI-related muscle spasms is mild or
moderate. Muscle spasms tend to occur more frequently at
night and in the muscles of the lower leg and foot, although
they can occur in any location. The impact of muscle spasms
is compounded given their high incidence (50%) in elderly
individuals [31]. They are thought to occur as a result of
paradoxical activation of the noncanonical SMO/Ca21/AMPK
axis and inhibition of the canonical SMO signaling pathway,
resulting in an influx of Ca21 into muscle cells and, sub-
sequently, immediatemuscle contraction [29].Muscle spasms
Table 1. Overview of key hedgehog pathway inhibitor studies providing safety data
Trial Design Treatment Population Primary objective Analyses
ERIVANCEBCC Single-arm,
open-label, pivotal
phase II study
Vismodegib 150 mg
once daily
aBCC (N5 104) Objective response rate • Primary analysis [6]
•12-monthanalysis [7]
• 30-month (final)
analysis [8]
U.S. EAP Single-arm,
open-label,
U.S.-based expanded
access study
Vismodegib 150 mg
once daily
aBCC (N5 119) To provide access to
vismodegib before
commercial availability
Final analysis [9]
STEVIE Single-arm,
open-label phase II
study
Vismodegib 150 mg
once daily
aBCC (N5 1,227) Incidence of AEs Interim analysis of 499
patients with potential
to be followed up for
$12 months [12]
RegiSONIC Prospective,
observational
U.S.-based disease
registry
Clinician standard of
care
aBCC; (109 patients
with laBCC treated
with vismodegib:
September 11,
2015)
Describe real-world
treatment patterns and
outcomes associated
with aBCC
Interim analysis of the
first 109 patients with
laBCC treated with
vismodegib (clinical
cutoff date September
11, 2015) [10]
Operable BCC Nonrandomized,open
label, three-cohort
phase II study
Continual vismodegib
150mgoncedaily for 12
weeks followed by
surgery (cohort 1)
Operable BCC
(N5 74); cohort 1
(n5 24), cohort 2
(n5 25), cohort 3
(n5 25)
Complete histologic
clearance rate
Final analysis [11]
Continual vismodegib
150mgoncedaily for 12
weeks, followed by 24
weeks of observation,
then surgery (cohort 2)
Intermittent
vismodegib 150 mg
once daily (8 weeks on/
4weeks off/8weeks on)
followed by surgery
(cohort 3)
BOLT Multicenter,
randomized,
double-blind, phase II
study
200 mg or 800 mg oral
sonidegib daily
aBCC (N5 230);
200 mg (n5 79)
and 800 mg
(n5 151 ITT;
n5 150 safety)
Objective response rate Primary analysis [5]
Abbreviations: aBCC, advanced basal cell carcinoma; AE, adverse event; BOLT, Basal Cell Carcinoma Outcomes with LDE225 Treatment; EAP, expanded
access program; laBCC, locally advanced BCC; STEVIE, Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma.
www.TheOncologist.com ©AlphaMed Press 2016
Lacouture, Dre´no, Ascierto et al. 3
Published Ahead of Print on August 10, 2016 as 10.1634/theoncologist.2016-0186. 
 by guest on A
ugust 16, 2016
http://theoncologist.alpham
edpress.org/
D
ow
nloaded from
 
are typically the most frequently observed AE during HPI
treatment (49%–76% of all patients) and usually occur early in
the course of treatment (Table 2).
The recommendedmanagement algorithm is presented in
Figure 2A. Patients should be advised to maintain adequate
hydration and gentle physical activity while taking an HPI.
Laboratory testing isnot required, accordingto thevismodegib
label, although for sonidegib, creatinekinase (CK) levels should
be assessed before treatment and periodically as clinically
indicated. Any additional laboratory testing is at the discretion
of the treating physician. A number of nonpharmacologic
approaches can be used for grade 1–2 muscle spasms, with
anecdotal benefit reported with passive stretching (these
techniques can be easily taught to the patient by a physi-
cal therapist) [32], heating therapy, cryotherapy (ice) [33],
exercise, massage, peripheral transcutaneous electrical stim-
ulation (for localized cramps) [34], splinting of affected areas
while sleeping, and changes in sleeping or sitting position [35].
Althoughhydration is frequentlyused, especiallywhencramps
are associated with exercise, no formal evidence supports
hydration as a mechanism to reduce cramping. A number of
pharmacologic treatments may be used for initial grade 1–2
symptoms, including calcium channel blockers (i.e., amlodi-
pine [36]), diltiazem [37], verapamil [38], sports drinks (those
that replace electrolytes), and nerve stabilizers (e.g., gaba-
pentin or pregabalin) [39]. Magnesium supplementation has
also been studied, and only a small, nonsignificant difference
has been reported in reducing the frequency of idiopathic
cramping [40]. Lidocaine [41], levetiracetam [42], vitamin B
complex [43], naftidrofuryl (not available in the United States)
Table 2. Summary of safety data from key hedgehog pathway inhibitor studies
Parameter
ERIVANCE BCC
EAP [9]
N5 119
STEVIE [12]
N5 499
RegiSONIC [10]a,b
n5 109
Operable
BCC [11]
N5 74
BOLT [5]
N5 230
Primary
analysis [6]
N5 104
12months [7]
N5 104
30months [8]
N5 104
200mg,
n5 79
800mg,
n5 150
Any AE, % 100 100 100 98 98 82 99 95 100
Muscle
spasms
68 71 71 71 64 53 76 49 67
Alopecia 64 65 66 58 62 46 58 43 55
Dysgeusia 51 54 56 71 54 60c 50 38 59
Weight loss 46 50 52 16 33 N/A N/A 27 38
Fatigue 36 40 43 19 16 N/A 20 29 36
Nausea 29 33 33 19 16 N/A 18 33 45
Loss of
appetite
23 27 28 N/A 25 N/A 11 19 31
Diarrhea 22 26 27 25 17 N/A 8 24 22
Median time
to onset of AE
Muscle
spasms
N/A 1.89 months N/A 37 days 2.83 months 36 days N/A N/A N/A
Alopecia N/A 3.38 months N/A 87 days 5.55 months 105 days N/A N/A N/A
Dysgeusia N/A 1.8 months N/A 41 days 6.51 months 51 days N/A N/A N/A
Weight loss N/A 6.13 months N/A 175 days N/A N/A N/A N/A N/A
Fatigue N/A 2.79 months N/A 42 days N/A N/A N/A N/A N/A
Nausea N/A 2.14 months N/A 30 days N/A N/A N/A N/A N/A
Loss of
appetite
N/A 2.87 months N/A N/A N/A N/A N/A N/A N/A
Diarrhea N/A 4.47 months N/A 38 days N/A N/A N/A N/A N/A
Median
duration of
treatment,
months
9.8 12.9 12.9 5.5 8.4 N/A 2.8 8.9 6.5
Discontinued
treatment, %
51 72 92 100d 80 N/A 34 51 69
Due to AEs 12 17 21 4 36 19 5 20 32
aVismodegib-treated patients with laBCC.
bData in the RegiSONIC column refer to vismodegib-related AEs.
cIncludes dysgeusia and ageusia.
dSponsor study termination was the primary reason for discontinuation (79 patients transitioned to commercial drug).
Abbreviations: AE, adverse event; BCC, basal cell carcinoma; BOLT, Basal Cell Carcinoma Outcomes with LDE225 Treatment; EAP, expanded access
program; laBCC, locally advanced basal cell carcinoma; N/A, not available; RegiSONIC, An Observational Study of Treatment Patterns and Effectiveness
and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients; STEVIE, Study of Vismodegib in Patients
With Locally Advanced or Metastatic Basal Cell Carcinoma.
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[44], and cyclobenzaprine [45] have also all demonstrated
effectiveness. Forsymptomsthathavespreadto theabdomen,
calcium channel blockers (i.e., amlodipine) and antimotility
(e.g., loperamide), antimuscarinic (e.g., trimebutine), or anti-
cholinergic agents (e.g., scopolamine) may be useful. Although
a number of agents, including vitamin E, baclofen, riluzole,
L-threonine, xaliproden, indinavir, memantine, carbamazepine,
and oxcarbazepine, have been investigated in patients with
amyotrophic lateral sclerosis/motor neuron disease, none has
shown any significant benefit in reducing cramping [46].
The FDA has advised against the use of quinine for cramps
because of potentially dangerous and life-threatening side
effects (QT prolongation, thrombocytopenia, and hypersensi-
tivity reactions) [47], although, in non-U.S. countries, cautious
use for severe cramps is permitted. The American Academy
ofNeurology recommends that quinine could be considered
in select patients (i.e., in those whom cramps are disabling,
no other agents relieve symptoms) after potential AEs are
evaluated [48]. No adverse interactions have been reported
with the use of HPIs and quinine.
For muscle spasms grade$3 reported during vismodegib
treatment, experience indicates that at least two cycles of
vismodegib treatment interruption (2–4 weeks each time)
should be attempted before treatment discontinuation is
considered. Anecdotal experience with use of a change in the
dosing regimen (e.g., week on/week off) to mitigate spasms
hasalsobeenreported. In theoperableBCCstudy,mostmuscle
spasms resolved within 6 weeks of treatment discontinuation
[11]. Currently, a randomized, double-blind crossover study is
recruiting patients to assess the effects of levocarnitine (vs.
placebo) on the incidence and severity of vismodegib-related
muscle spasms (ClinicalTrials.gov identifier NCT01893892).
Limited information isavailableonsonidegib in thisaspect, and
there are no ongoing trials. The Muscle and Joint Measure
(available from:https://www.fredhutch.org/content/dam/public/
labs-projects/clinical-research/biobehavioral/MJM_updated_
1-15-10_Syrjala_et_al_PDF.pdf) is a patient-reported outcomes
tool used to measure musculoskeletal symptoms in cancer
survivors and patients with spinal cord injuries, and it might be
useful inassessmentof the impactofmuscle spasmsandresponse
to therapy [49, 50].
Taste Disturbances (Dysgeusia/Ageusia)
Severity of the loss (ageusia) or distortion (dysgeusia) of the
sense of taste can range and can affect oral intake; it may even
cause anorexia anddepression.Gustation is important forQOL
and can be affected by age, medication, and comorbidity [51].
Approximately 5% of the general population reports taste
alterations, which increases progressively to 27% in those
older than 80 years [52]. In patients with cancer, dysgeusia
affects 56.3% of those treated with chemotherapy, 66.5% of
those treated with radiotherapy, and 76% of those treated
with combined chemotherapy and radiation [53]. In patients
receiving chemotherapy, increased thresholds for bitter,
sweet, sour, and salt tastes have been reported, whereas no
difference has been reported for umami taste [54].
Hedgehog pathway signaling has been found to regulate
differentiation and maintenance of taste buds [20, 55].
Vismodegib decreases the number of Shh-expressing type IV
taste cells [21], which have been shown to be critical for taste-
bud differentiation in adults. Taste disturbances occur in
50%–71%ofvismodegib-treatedpatients, typicallydeveloping
within the first few months of treatment (Table 2). In the
sonidegib BOLT study, dysgeusia was reported in 38%
and 59% of patients in the 200-mg and 800-mg groups,
respectively [5]. Assessing taste changes in patients treated
with HPIs may be challenging given the subjective nature;
interestingly, a Taste and Smell Survey was used to evaluate
improvement in chemosensory perceptions in a study of delta-9-
tetrahydrocannabinol [56], and it might be useful in patients
treated with HPIs.
When managing this particular AE, it is important to
recognize that the symptomsmaybe independent ofobserved
weight loss. The recommended management algorithm is
presented in Figure 2B. Access to a nutritionist or dietitian at
baseline and throughout treatment is beneficial [57], and the
patient should be reminded to maintain adequate caloric
intake and hydration. Dietary counseling has resulted in
reduction in the occurrence of both early-onset and long-term
dysgeusia. Similar effects were found with audiotapes and
written information that was mailed to patients [53]. In
addition, specific recipes given to patients, information on the
use of flavor enhancers, and detailed nutritional information
Figure 1. Adverse events associated with hedgehog pathway inhibitors [19, 21, 26, 29].
Abbreviations: b.i.d., twice daily; Tx, treatment.
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haveresulted inbetter reportingof tasteperception inpatients
receiving chemotherapy [58]. Strategies such as adding spicy
ingredients,marinatingmeat, cooling foods, and adding sweet
ingredients tomeat have alsobeenhelpful. Cold foods seemto
lessen metallic taste. Other helpful advice for patients, based
on experience of the experts, included using new recipes,
honoring specific food cravings, eating candy before meals,
cutting foodwith lemon, using sweetened drinks, using plastic
utensils, drinking from a straw, brushing the teeth and tongue
before meals, and using a baking soda-salt wash or an
antibacterialmouthwash.Giventhehalf-lifeofHPIsandthe life
span of taste cells (10–24 days), it is likely the interruptions
caused by dysgeusia require at least 4 weeks for recovery
of gustation, although, in some cases, it can take as long as
6 months to return. Patients should attempt to restart HPIs
if interruption is necessary.
A pilot study investigating delta-9-tetrahydrocannabinol
compared with placebo in 24 patients with idiopathic
dysgeusia showed improved chemosensory perception, food
taste, appetite, and calories consumed [56]. In patients with
idiopathic dysgeusia, zinc gluconate supplementation resulted
in improved taste (p, .05) [59];however, contradictory results
were seen in two studies of patients receiving radiotherapy for
head and neck squamous cell carcinoma [60].
Apilot study investigatingdelta-9-tetrahydrocannabinol
compared with placebo in 24 patients with idiopathic
dysgeusia showed improvedchemosensoryperception,
food taste, appetite, and calories consumed.
Alopecia
There are approximately 100,000 hairs on the scalp, of which
approximately 90% are in the anagen (growth) phase; the
remainder are in the catagen (involuting or resting) and
telogen(restingorquiescent)phases.Hairplaysacritical role in
the psychosocial well-being of patients, and its loss has been
associatedwithdecreasedQOL,depression,andisolation.Alopecia
with HPIs is usually characterized by diffuse loss of hair density
Figure 2. Proposed treatment algorithms based on anecdotal evidence discussed at the expert meeting. (A):Muscle spasms. (B): Taste
disturbance. (C): Alopecia. (D):Weight loss. (E): Fatigue. Per CTCAE, for grade$3 events, at least 2 treatment interruptions (2–4 weeks)
should be attempted before treatment discontinuation is considered.
Abbreviations: b.i.d., twice daily; CTCAE, Common Terminology Criteria for Adverse Events; DHT, dihydrotestosterone; HCP, health
care professional; HPI, hedgehog pathway inhibitor; QD, once daily; THC, delta-9-tetrahydrocannabinol.
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over the entire scalp and may affect the eyebrows, eyelashes,
and beard. Hair texture and quality is also often changed.
Hedgehog pathway inhibitors are thought to induce
alopecia by preventing follicles from transitioning to the
anagen phase after shedding of hair in the telogen phase [61].
Alopecia occurs in 46%–66% of vismodegib-treated patients
and has a longer time to onset than is observed with cytotoxic
chemotherapy,developingafterat least2monthsof treatment
(Table2). In the sonidegibBOLTstudy, alopeciawas reported in
43% and 55% of patients in the 200-mg and 800-mg groups,
respectively [5]. The severity of alopecia can be exacerbated
because of the normal development of alopecia (40%–70% of
individuals) as part of the aging process. The psychosocial
impact of alopecia as reported by a patient can be captured
Figure 2. Continued.
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using the Hairdex questionnaire [62]. In the interim analysis of
the STEVIE study, treatment was discontinued because of
alopecia in 4.2% of patients [12]. In the operable BCC study
(cohort 2: 12 weeks of vismodegib and 24 weeks of
observation), most cases of alopecia (13 of 17 patients)
resolved within 24 weeks of treatment discontinuation [11].
Interestingly, alopecia with use of vismodegib might be more
pronounced and longer lasting in patients with BCCNS [63].
Patients should be reminded that the alopecia is unlike that
caused by traditional cytotoxic chemotherapy. Alopecia typically
develops gradually, and, in some cases, can be delayed and
actually occur after HPI treatment has been halted. Alopecia
associatedwith HPI treatment can also be persistent and, in rare
cases, might be permanent [64]. Supportive care includes the
identification of comorbidities that might contribute to
alopecia and use of minoxidil, oral dihydrotestosterone
inhibitors (i.e., spironolactone, finasteride), and camouflag-
ing methods (i.e., sprays, powders, hairpieces, and wigs)
(Fig. 2C).
Weight Loss
Cancer-related weight loss occurs frequently and may be
associatedwith theunderlyingdisease,depression,or therapy.
An international consensus defined cancer anorexia-cachexia
as a multifactorial syndrome, with weight loss .5% over the
past 6 months or weight loss .2% in individuals already
showing depletion [65]. Weight loss was reported in approx-
imately 50% of patients in the ERIVANCE BCC analyses [6–8],
with lower incidence (33%) observed in the real-world STEVIE
study [12]. In the BOLTstudy, weight loss was reported in 27%
and 38% of patients in the 200-mg and 800-mg sonidegib
groups, respectively [5]. Onset is generally seen 6 months
Table 3. Summary of drugs and doses for prevention or treatment of some of the hedgehog pathway inhibitor-related AEs
Symptom
treated Drug Indication Dose
Administration
method
Muscle spasms Amlodipine High blood pressure and chest pain Up to 10 mg/day Oral
Muscle spasms Gabapentin Postherpetic neuralgia in adults;
adjunctive therapy in treatment of
partial-onset seizures
300–900 mg/day (can be titrated
up to 1,800 mg/day) (neuralgia)
Oral
300–600 mg t.i.d. (seizures)
Muscle spasms Pregabalin Neuropathic pain associated with
diabetic peripheral neuropathy;
postherpetic neuralgia; partial-onset
seizures; fibromyalgia; neuropathic
painassociatedwith spinal cord injury
100 mg t.i.d. (diabetic peripheral
neuropathy); 75–150 mg b.i.d.
or 50–100 mg t.i.d. (postherpetic
neuralgia); 150–600mg/day(seizures);
300–450 mg/day (fibromyalgia);
150–600 mg/day (neuropathic pain
associated with spinal cord injury)
Oral
Muscle spasms Cyclobenzaprine Adjunct to rest and physical therapy
for relief ofmuscle spasms associated
with acute, painful musculoskeletal
conditions
5 mg t.i.d. May be increased to
10 mg t.i.d.
Oral
Diarrhea Loperamide Diarrhea; reduce amount of stool in
individuals with an ileostomy
2 mg up to 8–16 mg/day Oral
Diarrhea Trimebutine Symptoms of irritable bowel
syndrome
200 mg t.i.d. Oral
Nausea and
vomiting
Scopolamine Sedative and tranquilizing depressant
to the central nervous system
1.5 mg every 3 days Transdermal
Alopecia
(eyelashes)
Bimatoprost Increasing thickness, length, and
darkness of eyelashes
One drop (0.03%) along the skin
of the upper eyelid every evening
Topical
Alopecia Finasteride Male pattern alopecia 1 mg/day in men; 5 mg/day in women Oral
Alopecia Minoxidil Male and female pattern alopecia 5% one to two times daily Topical
Nausea Ondansetron Nausea and vomiting 8 mg b.i.d. Oral
Weight loss,
nausea
Tetrahydrocannabinol Anorexia, nausea Capsules every evening Oral
Weight loss Fish oil Weight loss 12 tablets (consisting of 18%
EPA and 12% DHA) daily
Oral
Nausea and
weight loss
Metoclopramide Nausea and vomiting, anorexia 10 mg four times daily Oral
Weight loss BCAA
supplementation
Anorexia BCAA 4.8 g t.i.d. (leucine 2.36 g,
isoleucine 1.28 g, and valine 1.16 g)
Oral
Weight loss Megestrol acetate Anorexia Initiate at 160 mg daily up to a
maximum of 800 mg daily
Weight loss Corticosteroids Nausea and vomiting Prednisone, 5 mg t.i.d.
Dexamethasone, 3–6 mg daily
Abbreviations: AE, adverse event; BCAA, branched-chain amino acid; b.i.d., twice daily; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid;
t.i.d., three times daily.
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after the start of treatment [7]. Although muscle mass is
often lost, there does not seem to be a correlation between
weight loss and taste disturbances, and body weight typi-
cally returns to previous levels after treatment interrup-
tion. Ongoing evaluations by a nutritionist can be helpful,
and supplements can be useful for patients at risk for
weight loss (including elderly individuals; those with low
bodymass index or significant comorbidities; or those who
live alone). Vismodegib administration can be interrupted
for up to 8 weeks, followed by discontinuation if necessary
(Fig. 2D).
Asthenia
Asthenia (or fatigue) is defined by the National Comprehen-
sive Cancer Network (NCCN) as a distressing, persistent, and
subjective sense of physical, emotional, or cognitive tiredness
or exhaustion related to cancer or cancer treatment that is not
proportional to recent activity and that interferes with usual
functioning [66]. In HPI-treated patients, asthenia can also
be influenced by a number of factors, including interrupted
sleep patterns because ofmuscle spasms, or decreased caloric
intake because of taste disturbances. Patients should be as-
sessed and treated appropriately for depression and ques-
tionedaboutgeneral fatigue,physical fatigue, reducedactivity,
reduced motivation, and mental fatigue. NCCN guidelines
recommend patient education (especially at the start of
treatment), togetherwithphysical activity, yoga, other physical-
based therapies, psychosocial interventions, nutritional consul-
tation, sleep therapy, and management of comorbidities (e.g.,
pain, insomnia, depression) [66]. Provider-directed National
Cancer Institute recommendations also include the use of
psychostimulants, along with anemia treatment, cognitive
behavioral therapy, and rest [67]. Although there is little
evidence to support the use of pharmacologic intervention
(e.g., methylphenidate) [68, 69], because depression and
HPI-induced fatigue are concomitant factors in patients with
advanced BCC, these agents might play a role. Self-report
instruments to measure fatigue are available [70], and the
American Society of Clinical Oncology published guidelines for
the management of fatigue in cancer survivors that might be
useful [71]. The proposed management algorithm is presented
in Figure 2E.
Nausea
Nausea is often the first AE to be reported and it can be
challenging to manage. Vismodegib and sonidegib are consid-
eredmoderate to highly emetogenic oral antineoplastic agents
by the NCCN, and NCCN guidelines for the prevention or oral
chemotherapy-related antiemesis include the use of serotonin
inhibitors, to be started before initiation and continued daily.
For breakthrough emesis, recommendations are based on
adding one agent from a different drug class to the current
regimen and, if emesis is controlled, continuing on a schedule.
Breakthrough agents include the atypical antipsychotic olanzapine,
the benzodiazepine lorazepam, cannabinoids (such as dronabi-
nol and nabilone), phenothiazines, steroids, and others, such as
haloperidol, metoclopramide, and scopolamine [72]. Patient
education is important so patients knowwhat to expect during
treatment. Nonmedical interventions include taking vismode-
gib at nighttime or with food. Gastrointestinal motility medi-
cations (e.g., domperidone)orantinauseamedications (e.g.,
dimenhydrinate), are useful medical interventions. Drugs that
alter the pH of the upper gastrointestinal tract (e.g., proton
pump inhibitors, H2-receptor antagonists, and antacids)might
alter the solubility of vismodegib and reduce bioavailability.
However, results of a clinical study did not show clinically
significant pharmacokinetic interaction between vismodegib
and rabeprazole (a protonpump inhibitor) in healthy volunteers
Figure 3. BCC treatment symptoms checklist for hedgehog pathway inhibitor-associated adverse events.
Abbreviation: BCC, basal cell carcinoma.
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(unpublished data; Roche). If symptoms do not improve,
treatment interruption or a change in dosing regimens should
be the next step, with discontinuation as the final option.
Other AEs
Components of the hedgehog signaling pathway play a
functional role in the ovaries of mature rodents [73, 74], and,
in phase I and II trials, amenorrhea or irregular menses
occurred in 10 of 35 premenopausal female patients (28.5%)
treated with vismodegib [75]. Resolution of amenorrhea in
some patients has been observed after discontinuation of
vismodegib. HPIs can affect female fertility; consequently,
fertility preservation strategies should be discussed with
women of childbearing age before starting treatment with
HPIs.HPIs are teratogenic in animals and, inhumans, can result
inembryo-fetaldeathorseverebirthdefects. Pregnancy status
should be verified before treatment with HPIs in women of
childbearing potential, and patients should be informed of the
need for contraception.
HPIs are teratogenic in animals and, in humans, can
result in embryo-fetal death or severe birth defects.
Pregnancy status should be verified before treat-
ment with HPIs in women of childbearing potential,
and patients should be informed of the need for
contraception.
For sonidegib-treated patients, CK levels should be assessed
before treatment and periodically as clinically indicated.
Additional laboratory testing is at the discretion of the treating
physician. Elevated CK levels were observed in 29% and 37% of
patients treatedwith sonidegib 200mgand800mg, respectively
[5]. Patients starting therapy with sonidegib must be informed
of the risk for muscle-related AEs, including rhabdomyolysis.
Patients should be carefully monitored during treatment and
advised to promptly report any unexplained muscle pain,
tenderness, orweakness. Patientswith neuromuscular disorders
and those in whom sonidegib is administered in combination
with agents that can increase the risk for muscle toxicity (e.g.,
3-hydroxy-3-methylglutaryl-coenzyme [HMG-CoA] reduc-
tase inhibitors) shouldbefollowedupcarefully.Accordingtothe
vismodegib label, laboratory testing forCK level isnotnecessary.
CONCLUSION
Hedgehog pathway inhibitors could be an important treat-
mentoption for patientswith advancedBCC—apopulation for
whom options were previously limited. The safety profile of
vismodegib was consistent during long-term follow-up and
across a number of clinical trials. Although the severity of the
AEs typically associated with treatment is mostly grade 1 or 2,
the long-term nature of these AEs can lead patients to dis-
continue treatment. Moreover, patients with complete re-
sponse toHPIs tend todiscontinue treatmentbecauseof these
common AEs more frequently than patients with no response
or with partial response, who might discontinue only because
ofmore severe AEs. Evidence also suggests that changing HPIs
will not lead to significantly different AEs, underscoring the
importance of maintaining patients on therapy with the first
HPI administered and providing sufficient support to manage
AEs to maximize effectiveness.
Assessing the QOL of patients treated with HPIs is critical
because discrepancies have been seen in how HCPs and
patients grade the severity of AEs [76]. A patient-reported
outcomes questionnaire has been developed for patientswith
advanced BCC and BCCNS; however, this questionnaire is not
specifically designed to capture AEs unique to HPIs [30]. A
symptom questionnaire has been developed for use in
vismodegib-treated patients (Fig. 3), and its use might aid in
ascertaining the impact of these events in patient QOL and aid
in supportive care interventions. Studies in BCC populations
are ongoing to further explore an optimal dosing regimen for
vismodegib [77, 78]. In addition, data indicate that the safety
profile of vismodegib is comparable in elderly patients and
youngerpatients[79].Toensuremaximumbenefit fromtherapy,
use of the management recommendations presented here
might enable HCPs to maintain QOL in patients taking HPIs.
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